Cadrenal Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc. filed a Form 8-K regarding a Nasdaq listing-compliance notice. The earliest reported event occurred on September 6, 2023; the report was signed on September 8, 2023. The company is incorporated in Delaware, trades under the symbol CVKD on the Nasdaq Capital Market, and identifies as an emerging growth company.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Material Change Versus Prior Period
On September 6, 2023, Nasdaq notified the company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. The company’s closing bid price had remained below $1.00 for 30 consecutive business days.
Outlook, Risks, and Contingencies
- The notice had no immediate effect on the continued listing of the company’s common stock, subject to compliance with other Nasdaq requirements.
- The company had 180 calendar days, through March 4, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
- If compliance was not regained during the initial period, the company could be granted an additional 180 calendar days.
- If Nasdaq subsequently issued a delisting notice, the company would have the right to request a hearing before the Nasdaq Hearing Panel.
- Management stated that it would monitor the stock price and consider available alternatives, including a reverse stock split if necessary.
Important Facts for Investors to Verify
- Whether the company regained compliance by March 4, 2024 or received an additional compliance period.
- Any subsequent Nasdaq delisting notice, hearing request, or listing-status determination.
- Whether the company implemented a reverse stock split or another action affecting the share count or stock price.
- The company’s current cash position, financing needs, operating results, and dilution exposure, none of which are disclosed in this filing.